SGH-Shimadzu Personomics Centre Towards Advanced Healthcare

Singapore General Hospital (SGH) and Shimadzu (Asia Pacific) have taken a significant step in healthcare innovation with the launch of the SGH-Shimadzu Personomics Centre. This collaboration was formalized on 22 November 2024 with the signing of a Memorandum of Understanding (MOU).

The launch event was graced by the presence of Professor Ng Wai Hoe, Group CEO of SingHealth; Yasunori Yamamoto, President & CEO of Shimadzu Corporation; Prem Anand, Managing Director of Shimadzu (Asia Pacific); Professor Kenneth Kwek, CEO of SGH; Professor Tan Hiang Khoon, CEO (Designate) of SGH; and Professor Ruban Poopalalingam, Chairman of the Medical Board, SGH.

Advancing Personalized Treatment To Improve Quality Care For Patients

The SGH-Shimadzu Personomics Centre is set to redefine patient care by focusing on several key initiatives. A primary objective is developing and validating workflows for antibiotic therapeutic drug monitoring, crucial for effectively treating complex and hard-to-treat bacterial infections.  

The Centre will also prioritize translational research to bridge the gap between laboratory discoveries and clinical applications. By accelerating the development of personalized treatment plans and enabling faster, more accurate diagnoses, this initiative is expected to bring tangible benefits to patients and drive impactful healthcare solutions forward. 

A Collaborative Approach For Greater Healthcare Innovation

This partnership unites SGH’s extensive clinical expertise with Shimadzu’s innovations in analytical technologies, signifies a forward-looking commitment to innovating and enhancing personalized care.  

Together, they aim to advance diagnostics and treatment, improving overall patient care and setting new benchmarks in medical advancements. With this collaboration, the synergy between the two organizations will drive healthcare solutions that address medical challenges with a data-driven approach.